Back to Journals » OncoTargets and Therapy » Volume 2

Targeted therapy in the treatment of malignant gliomas

Authors Lukas RV, Boire A, Nicholas K

Published 13 May 2009 Volume 2009:2 Pages 115—133


Review by Single anonymous peer review

Peer reviewer comments 4

Rimas V Lukas1, Adrienne Boire2, M Kelly Nicholas1,2

1Department of Neurology; 2Department of Medicine, University of Chicago, Chicago, IL, USA

Abstract: Malignant gliomas are invasive tumors with the potential to progress through current available therapies. These tumors are characterized by a number of abnormalities in molecular signaling that play roles in tumorigenesis, spread, and survival. These pathways are being actively investigated in both the pre-clinical and clinical settings as potential targets in the treatment of malignant gliomas. We will review many of the therapies that target the cancer cell, including the epidermal growth factor receptor, mammalian target of rapamycin, histone deacetylase, and farnesyl transferase. In addition, we will discuss strategies that target the extracellular matrix in which these cells reside as well as angiogenesis, a process emerging as central to tumor development and growth. Finally, we will briefly touch on the role of neural stem cells as both potential targets as well as delivery vectors for other therapies. Interdependence between these varied pathways, both in maintaining health and in causing disease, is clear. Thus, attempts to easily classify some targeted therapies are problematic.

Keywords: glioma, EGFR, mTOR, HDAC, Ras, angiogenesis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.